VAL ValiRx plc
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. It is also involved in the development of BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment of SARS-CoV2 infection; and CLX001, a peptide in a nanoparticle formulation for the treatment of triple negative breast cancer. The company was founded in 2006 and is based in London, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About ValiRx (LON: VAL)
›
ValiRx (LON: VAL) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 0.1400 GBp on 20 November 2026, down 40.4% over 52 weeks. Its 52-week range is 0.1200 GBp to 0.4800 GBp: the price is 70.8% below the high and 16.7% above the low.
Its market capitalisation is 1.85M GBP.
ValiRx reports return on equity of -78.2%.
It holds more cash than debt, a net cash position of 970.56K GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.